AZNAstraZenecaSigning up patients
Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
Solid Tumours
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 180 (planned)
- Started
- Mar 17, 2026
- Main results expected
- Mar 29, 2030
- Fully finished
- Mar 29, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Parts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Measured over: From Screening (Day -28) to follow-up (up to 3.5 years)
Part B: Progression free survival (PFS)
Measured over: Up to 3.5 years
Part A - Number of participants with dose-limiting toxicities (DLTs)
Measured over: Up to 28 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07446855 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC